The pharmaceutical industry's focus on rare diseases has intensified, with 57% of all novel drugs approved in 2025 designated as orphan treatments. This is a continued increase from prior years, indicating a strategic shift towards smaller patient populations with high unmet needs, as exemplified by three different drugs for Hereditary Angioedema (HAE) being approved within ten weeks.

The company's genesis was unconventional. It was founded by Bob Yant, a patient with a spinal cord injury, who proactively sought out leading researchers to translate promising science into therapies. This patient-driven model highlights an alternative pathway for biotech creation, where the 'problem' finds its 'solution' in academia.

An investment from the nonprofit Beyond Celiac provides more than capital; it offers powerful third-party validation for a novel therapeutic target. For investors and potential pharma partners, this endorsement from a patient organization helps de-risk a new technology and demonstrates a clear patient need and interest.

Gamma secretase inhibitors, a class of drugs initially developed for Alzheimer's disease and later failed in other solid tumors, were successfully repurposed for desmoid tumors. This was due to their specific activity on the Wnt/Notch signaling pathways that drive this rare disease.

For rare diseases without established clinical endpoints, biotech firms should co-design new endpoints with patients and their families. Presenting these patient-centric measures to the FDA builds a bond of trust and provides the agency with a clear, meaningful rationale for drug approval.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

The approval of effective therapies like nirogacestat creates an ethical dilemma. For patients with progressing tumors, continuing to use a placebo arm in clinical trials may no longer be appropriate, challenging future research design for this rare disease.

Developing drugs for rare diseases demands a hands-on, dedicated approach. Unlike mass-market trials, it involves deep partnerships with busy academic centers and requires a company culture entirely focused on the unique, high-touch challenges of the space.

Effective patient advocacy in the Huntington's disease community involved more than raising awareness. Advocates achieved a regulatory reversal by directly engaging with lawmakers' offices, such as that of Senator Ron Johnson. This targeted political action was crucial in getting their concerns about the FDA's previous stance heard and ultimately changed.